Enhancing validity in co-occurring disorders treatment research

Schizophrenia Bulletin

Volumn 32, Issue 4, 2006, Pages 655-665

  McHugo, Gregory J ^a   Drake, Robert E ^a   Brunette, Mary F ^a   Xie, Haiyi ^a   Essock, Susan M ^b   Green, Alan I ^c  

^a DARTMOUTH PSYCHIATRIC RESEARCH CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Co occurring disorders; Dual diagnosis; Ecological validity; Effectiveness research; External validity; Inferential validity

Indexed keywords

ARTICLE; COMORBIDITY; EVIDENCE BASED MEDICINE; EXTERNAL VALIDITY; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE; OUTCOMES RESEARCH; PRIORITY JOURNAL; SUBSTANCE ABUSE; VALIDITY;

COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 33748774400     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbl009     Document Type: Article

References (64)

1. New Freedom Commission on Mental Health. Achieving the Promise: Transforming Mental Health Care in America. Rockville, Md. DHHS Publication No. SMA-03-3831; 2003.
2. Drake RE, Brunette MF. Complications of severe mental illness related to alcohol and other drug use disorders. In: Galanter M, ed. Recent Developments in Alcoholism. Volume XIV, Consequences of Alcoholism. New York: Plenum; 1998:285-299.
3. Caton CLM, Drake RE, Hasin D, et al. Differences between early phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry. 2005;62:137-145.
4. Petrakis IL, Nich CI, Ralevski E. Schizophrenia and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull. In press.
5. Lehman AF, Herron JD, Schwartz RP, Myers CP. Rehabilitation for young adults with severe mental illness and substance use disorders: a clinical trial. J Nerv Ment Dis. 1993;181:86-90.
6. Chandler DW, Spicer G. Integrated treatment for jail recidivists with co-occurring psychiatric and substance use disorders. Community Ment Health J. 2006;42:In press.
7. Hellerstein DJ, Rosenthal RN, Miner CR. A prospective study of integrated outpatient treatment for substance-abusing schizophrenic patients. Am J Addict. 1995;4:33-42.
8. Mueser KT, Drake RE, Sigmon S, Brunette MF. Psychosocial interventions for adults with severe mental illnesses and co-occurring substance use disorders: a review of specific interventions. J Dual Disord Diagn. 2005;1:57-82.
9. Brunette MF, Mueser KT, Drake RE. A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug Alcohol Rev. 2004;23:471-481.
10. Drake RE, Mueser KT, Brunette MF, McHugo GJ. Review of treatments for persons with severe mental illness and cooccurring substance use disorder. Psychiatr Rehabil J. 2004; 27:360-374.
11. Brunette MF, Noordsy DL, Buckley P, Green AI. Pharmacologic treatments for co-occurring substance use disorders in patients with schizophrenia: a research review. J Dual Diagn. 2005;1:41-55.
12. Campbell DT, Stanley JC. Experimental and Quasi-Experimental Designs for Research. Chicago, Ill: Rand McNally; 1963.
13. Cook TD, Campbell DT. Quasi-Experimentation: Design and Analysis Issues for Field Settings. Chicago, Ill: Rand McNally; 1979.
14. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston, Mass: Houghton Mifflin; 2002.
15. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999;156:5-10.
16. Carroll KM, Rounsaville BJ. Bridging the gap: a hybrid model to link efficacy and effectiveness research in substance abuse treatment. Psychiatr Serv. 2003;54:333-339.
17. Rothwell PM. External validity of randomized controlled trials: "to whom do the results of this trial apply?" Lancet. 2005;365:82-93.
18. Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would and would not qualify for an efficacy trial. Am J Psychiatry. 2005;162: 1370-1372.
19. Rounsaville BJ, Carroll KM, Onken LS. A stage model of behavioral therapies research: getting started and moving on from stage I. Clin Psychol Sci Pract. 2001;8:133-142.
20. Essock SM, Drake RE, Frank RG, McGuire TG. Randomized clinical trials in evidence-based mental health care: getting the right answer to the right question. Schizophr Bull. 2003;29:115-123.
21. Whitley R, Crawford M. Qualitative research in psychiatry. Can J Psychiatry. 2005;50:108-114.
22. Alverson H, Alverson M, Drake RE. An ethnographic study of the longitudinal course of substance abuse among people with severe mental illness. Community Ment Health J. 2000;36:557-569.
23. Alverson H, Alverson M, Drake RE. Social patterns of substance use among people with dual diagnoses. Ment Health Serv Res. 2001;3:3-14.
24. Wang PS, Demier O, Kessler RC. Adequacy of treatment for serious mental illness in the United States. Am J Public Health. 2002;92:92-98.
25. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv. 1996;47:853-858.
26. Bronfenbrenner U. The Ecology of Human Development: Experiments by Nature and Design. Cambridge, Mass: Harvard University Press; 1979.
27. Brunswick E. Perception and the Representative Design of Psychological Experiments. 2nd ed. Berkeley, Calif: University of California Press; 1956.
28. TenHave TR, Coyne J, Slazer M, Katz I. Research to improve the quality of care for depression: alternatives to the simple randomized clinical trial. Gen Hosp Psychiatry. 2003;25:115-123.
29. Collins LM, Murphy SA, Nair V, Strecher V. A strategy for optimizing and evaluating behavioral interventions. Ann Behav Med. 2005;30:65-73.
30. Lavorie PW, Dawson R. A design for testing clinical strategies: biased individually tailored within-subject randomization. J R Stat Soc Ser A Stat Soc. 2000;163:29-38.
31. Murphy SA. An experimental design for the development of adaptive treatment strategies. Stat Med. 2005;24:1455-1481.
32. Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry. 1999; 56:1109-1115.
33. Unutzer J, Katon W, Williams JW, et al. Improving primary care for depression in late life: the design of a multicenter randomized trial. Med Care. 2001;39:785-799.
34. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457-494.
35. Schneider LS, Tariot PN, Lydetosos CG, et al. National Institute of Mental Health Clinical Antipsychotic Trails of Intervention Effectiveness (CATIE): Alzheimer Disease trial methodology. Am J Geriatric Psychiatry. 2001;9:346-360.
36. Breslin FC, Sobell MB, Sobell LC, Cunningham JA, Sdao-Jarvie K, Borsoi D. Problem drinkers: evaluation of a stepped-care approach. J Subst Abuse. 1999;10:217-232.
37. Brooner RK, Kidorf M. Using behavioral reinforcement to improve methadone treatment participation. Sci Pract Perspect. 2002;1:38-48.
38. Lavorie PW, Rush AJ, Wisniewski SR, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry. 2001;50:792-801.
39. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;24:637-651.
40. Drake RE, McHugo GJ, Xie H, Fox M, Packard J, Helmstetter B. Ten-year recovery outcomes for clients with co-occurring schizophrenia and substance use disorders. Schizophr Bull. 2006;32:464-473.
41. McDermott PA, Alterman AI, Brown L, Zaballero A, Snider EC, McKay JR. Construct refinement and confirmation for the Addiction Severity Index. Psychol Assess. 1996;8:182-189.
42. McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. J Nerv Ment Dis. 1980;168:26-33.
43. Xie H, McHugo GJ, Helmstetter BS, Drake RE. Three-year recovery outcomes for long-term patients with co-occurring schizophrenic and substance use disorders. Schizophr Res. 2005;75:337-348.
44. Boothroyd RA, Banks SM, Evans ME, Greenbaum PE, Brown E. Untangling the web: an approach to analyzing the impacts of individually tailored, multicomponent treatment interventions. Ment Health Serv Res. 2004;6:143-153.
45. Kendall PC, Marrs-Garcia A, Nath SR, Sheldrick RC. Normative comparisons for the evaluation of clinical significance. J Consult Clin Psychol. 1999;67:285-299.
46. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59:12-19.
47. Speer DC. Clinically significant change: Jacobson and Truax (1991) revisited. J Consult Clin Psychol. 1992;60:402-408.
48. Kenny DA, Calsyn RJ, Morse GA, Klinkenberg WD, Winter JP, Trusty ML. Evaluation of treatment programs for persons with severe mental illness: moderator and mediator effects. Eval Rev. 2004;28:294-324.
49. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002;59:877-883.
50. MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A comparison of methods to test mediation and other intervening variable effects. Psychol Methods. 2002;7:83-104.
51. Drake RE, McHugo GJ, Clark RE, et al. A clinical trial of assertive community treatment for patients with co-occurring severe mental illness and substance use disorder. Am J Orthopsychiatry. 1998;68:201-215.
52. Essock SM, Mueser KT, Drake RE. Comparison of ACT and standard case management for delivering integrated treatment for co-occurring disorders. Psychiatr Serv. 2006;57: 185-196.
53. Sigmon SC, Stitzer ML. Use of a low-cost incentive intervention to improve counseling attendance among methadone maintained patients. J Subst Abuse Treat. 2005;29:253-258.
54. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335-1341.
55. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28:51-63.
56. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26:441-449.
57. Scott CK. A replicable model for achieving over 90% follow-up rates in longitudinal studies of substance abusers. Drug Alcohol Depend. 2004;74:21-36.
58. Swartz MS, Swanson JW, Wagner HR, Burns BJ, Hiday VA. Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. J Nerv Ment Dis. 2001;189:583-592.
59. Clark RE. Family support and substance use outcomes for persons with mental illness and substance use disorders. Schizophr Bull. 2001;27:93-101.
60. Xie H, Drake RE, McHugo GJ. Are there distinctive trajectory groups in substance abuse remission over 10 years? An application of the group-based modeling approach. Adm Policy Ment Health Ment Health Serv Res. 2006;33:423-432.
61. Osher FC, Kofoed LL. Treatment of patients with psychiatric and psychoactive substance use disorders. Hosp Community Psychiatry. 1989;40:1025-1030.
62. Corrigan JD, Bogner J, Lamb-Hart G, Heinemann AW, Moore D. Increasing substance abuse treatment compliance for persons with traumatic brain injury. Psychol Addict Behav. 2005;19:131-139.
63. Drake RE, Wallach MA, McGovern MP. Preventing relapses to substance use disorder among clients with severe mental illnesses: what do we know and what do we do next? Psychiatr Serv. 2005;56:1297-1302.
64. Abelson RP. Statistics as Principled Argument. Hillsdale, NJ: Lawrence Erlbaum; 1995.